

FACTSHEET



Specialty pharma meets M&A competence

CHEPLAPHARM is a family-owned pharmaceutical company, headquartered in Germany. We offer our branded products on a global level.



By focusing on an internationally oriented Buy and Build Strategy, we generate annually increasing growth rates. For 2019, CHEPLAPHARM plans for an annual turnover of 500 million EURO (2018: 292 million EURO¹).

*Being a European pharmaceutical company, it is our **vision** to strengthen CHEPLAPHARM's position as global player and to expand our international footprint.*

*It is our **mission** to offer high quality products so that our patients as well as our business partners and employees benefit from our success*

Track-Record

During the past 25 years, the owner family Braun together with its team successfully concluded more than 90 acquisitions with well-known pharmaceutical companies in more than 120 countries. The total deal value exceeds 1.3 billion EURO.

Our achievements are a solid foundation for our future development.

International Footprint

CHEPLAPHARM benefits from a growing international presence with a well-established partner network. Therefore, we are operating in more than 120 countries and are holding more than 650 registrations worldwide.

Our subsidiaries are located in strategically selected markets, such as the United States of America and France, both reinforcing our International Footprint.

¹ Including Net sales and sales/profit generated during the transitional phase of acquired products



How to reach us

CHEPLAPHARM Arzneimittel GmbH

Headquarter / Office
Ziegelhof 24
17489 Greifswald

Tel.: +49 (0) 3834 8539-0
Fax: +49 (0) 3834 8539-349

Internet: www.cheplapharm.com
Email: [info\[at\]cheplapharm.com](mailto:info[at]cheplapharm.com)

Our Portfolio

With a clearly defined focus on selected pharmaceutical brands and niche products we offer a diversified portfolio covering a range of therapeutic areas and indications.

Primary therapeutic areas:

- Cardiology: DILATREND[®]/CO-DILATREND[®], ALDACTONE[®], SOTALIX[®] and INHIBACE[®]/Plus
- Adiposity: XENICAL[®] and MYSIMBA[®]
- Infection Medicine: CYMEVENE[®], LARIAM[®] and FUNGIZONE[®]
- Gastroenterology: DEURSIL[®]/URSOLVAN[®] and QUESTRAN[®]
- Oncology: VESANOID[®], ETOPOPHOS[®] and VEPESID[®]
- Ophthalmology: VISUDYNE[®]
- Haematology: KONAKION[®] MM
- Sleeping disorders: ROHYPNOL[®]
- Emergency medicine: ANEXATE[®]
- Addiction medicine: DISTRANEURIN[®]/HEMINEVRIN[®]

Sales by Geographical Position

CHEPLAPHARM, with headquarters in Northern Germany, is characterized by its noticeable European presence. For 2019, it is our target to generate almost two thirds of our turnover in Europe. More than 31% of the company's planned turnover are assigned especially to Asia and the Americas. The remaining turnover is divided equally on the Rest of the World.

CHEPLAPHARM at a Glance

- We consequently pursue a Buy and Build Strategy and benefit from our extensive experience in M&A's and business transfers.
- We market branded niche products globally in more than 120 countries.
- We generate annually increasing growth rates.